Synthesis and Preclinical Evaluation of Medications to Treat Substance Use Disorders (SUDs) (R01)
ArchivedNational Institutes of Health
Description
The National Institute on Drug Abuse (NIDA) is soliciting grant (R01) applications to support the synthesis and preclinical evaluation of new molecular entities as potential treatments for Substance Use Disorders (SUDs). Responsive applications may include synthesis, identification, optimization and preclinical efficacy and/or safety assessment of lead compounds. Applications must provide timelines and decision-trees with go/no-go criteria to advance or discontinue testing a compound. Possible new molecular entities include, but are not limited to, small molecules, enzymes, antibodies, and vaccines. The goal is to identify candidate compounds and advance them towards Investigational New Drug (IND) submission.
Who can apply
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities / Indian housing authorities
- Native American tribal organizations (other than Federally recognized)
- Nonprofits with 501(c)(3) status (other than higher education)
- Nonprofits without 501(c)(3) status (other than higher education)
- Private institutions of higher education
- For-profit organizations other than small businesses
- Small businesses
- Others
Contact
NIH OER Webmaster<br/>FBOWebmaster@OD.NIH.GOV<br/>
FBOWebmaster@OD.NIH.GOV
- PostedMay 15, 2012
- ClosesAug 15, 2012
- Program funding$2,500,000
- CFDA93.279
Pro insight
Edit and export this grant’s proposal template, plus deadline reminders, similar-grant suggestions, and funder history — all available with Pro.
Unlock with Pro